Burnett Patrick sold $395K of ARQT
Burnett Patrick (See Remarks) sold 15,000 shares of Arcutis Biotherapeutics, Inc. (ARQT) at an average of $26.33 ($26.08–$26.52, $0.39M total) across 2 trades over 2026-08-11 to 2026-08-12.
How this was made
The 30-second read
Why it matters
The newest disclosed fact is the officer’s open-market sale details and post-transaction holdings. The text does not include any new company guidance, trial results, regulatory actions, or deal activity.
Market read
Traders may note the insider sale for sentiment monitoring, but there is no fundamental catalyst in the filing text.
What to watch
No context is provided on total compensation, tax obligations, or whether other insiders sold/bought around the same time, limiting inference from the transaction alone.
Background
The article is a SEC Form 4 insider transaction disclosure for Arcutis Biotherapeutics, Inc. (ARQT).
Ticker impact
Arcutis Biotherapeutics Form 4 shows officer Burnett Patrick sold 15,000 shares in open-market trades at about $26.08 to $26.52.
Low likelihood of a sustained price move; any reaction is likely brief and sentiment-driven.
The filing is a routine Form 4 open-market sale with no 10b5-1 plan stated and no accompanying operational or guidance change in the text.
Market effects
Minimal. Insider selling in a single biotech name does not establish a sector-wide signal from the provided text.
None indicated.
None indicated.
Counterpoint
The sale could be driven by personal liquidity needs rather than negative expectations, especially since the trades are spread across two days.
Key entities
- issuerArcutis Biotherapeutics, Inc.
US-listed biotech company subject of the Form 4 insider sale disclosure.
- insiderBurnett Patrick
Officer who sold 15,000 ARQT shares across two open-market trades.
